CATX logo

PERSPECTIVE THERAPEUTICS INC

CATXNYSE AMERICAN
๐Ÿ† #3388 by market capEarnings Nov 9US Equity
$2.62โ–ฒ $0.13 (+4.80%)
๐ŸŒ™ After hours$2.58โ–ผ 1.53%Regular close ยท extended-hours price shown
๐Ÿ””
Track CATX
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ฒ 4.8%
7dโ–ฒ 0.2%
14dโ–ผ 3.0%
30dโ–ผ 16.8%
ytdโ–ผ 4.7%
1yโ–ผ 24.1%
๐ŸฆMarket Cap
$299M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
-100.0%
Declining
๐Ÿ“ŠGross Margin
-419.4%
Thin
๐Ÿ’ตFCF Margin
-33111.2%
Thin
โš–๏ธP/S Ratio
816.4x
Expensive
Otter Score
48
Weak

Trading Snapshot

Day Range
$2.61 โ€“ $2.63
52-Week Range
$1.96 โ€“ $6.16
Volume
$2.61B
Avg Volume
$2.68B
Shares Outstanding
114.0M
Next Earnings
Oct 28, 2026

Fundamentals Snapshot

Annual Revenue
$366,000
Last Q Revenue
$81,000
P/E Ratio
-1.7
P/S Ratio
816.4x
EPS (TTM)
$-1.58
Dividend Yield
0.00%
Dilution (1yr)
+3386.9%

Why Investors Own CATX

  • โœ“High-growth profile โ€” revenue up +1.1% YoY with expanding US Equity exposure.
  • โœ“Healthy economics โ€” 66% gross margin and 10% free-cash-flow margin.
  • โœ“New products and segments could unlock additional revenue streams.
โš ๏ธ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

CATX logo

PERSPECTIVE THERAPEUTICS INC

CATX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0โ–ผ โˆ’100.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-58.6%โ–ผ โˆ’158.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnโ€™t profitable yet.
โˆ’$114Mโ–ฒ +70.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
โˆ’$95Mโ–ฒ +31.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerโ€™s slice.
74.3Mโ–ฒ +3386.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$27Mโ–ผ โˆ’$30M YoY
StockOtter ยท stockotter.space

About PERSPECTIVE THERAPEUTICS INC

Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle โ€“ from development and manufacturing to sales and marketing โ€“ of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)
๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿ’งDilutionโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Weak
48/100

Analyst Ratings

โ“˜
Consensus
Buy
20 analysts
Strong Buy4
Buy14
Hold2
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

Benzingaยท11d ago

This $3 Biotech Could Be Worth $11.45, Analyst Says

Perspective Therapeutics Inc. (NYSE:CATX) could benefit from growing interest in radiopharmaceutical cancer treatments, according to William Blair.

GlobeNewsWireยท15d ago

Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytrudaยฎ (Pembrolizumab) in FAP-ฮฑ Positive Solid Tumors

SEATTLE, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (โ€œPerspective,โ€ the โ€œCompany,โ€ โ€œwe,โ€ โ€œus,โ€ and โ€œourโ€) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatm

Globe News Wireยท18d ago

Perspective Therapeutics Announces Acceptance of VMT-ฮฑ-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026

SEATTLE, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatm

GlobeNewsWireยท18d ago

Perspective Therapeutics Announces Acceptance of VMT-ฮฑ-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026

SEATTLE, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (โ€œPerspective,โ€ the โ€œCompany,โ€ โ€œwe,โ€ โ€œus,โ€ and โ€œourโ€) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatm

Seeking Alphaยท28d ago

Perspective Therapeutics: 'Strong Buy' On Bamzireotide Navoxetan Reinforced Data And Phase 3 Plans

Perspective Therapeutics remains a โ€œStrong Buy,โ€ driven by durable clinical data and multiple near-term catalysts across its radiopharmaceutical pipeline. The company's bamzireotide navoxetan for SSTR2-expressing NETs sh

Defense WorldยทAug 14

Dimensional Fund Advisors LP Acquires 358,540 Shares of Perspective Therapeutics, Inc. $CATX

Dimensional Fund Advisors LP raised its holdings in Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) by 391.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund own